• 1
    Parkin DM,Bray F,Ferlay J,Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
  • 2
    Hardcastle JD,Chamberlain JO,Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996; 348: 1472-1477.
  • 3
    Jorgensen OD,Kronborg O,Fenger C. A randomised study of screening for colorectal cancer using faecal occult blood testing: results after 13 years and 7 biennial screening rounds. Gut. 2002; 50: 29-32.
  • 4
    Mandel JS,Church TR,Ederer F,Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999; 91: 434-437.
  • 5
    Moss SM,Hardcastle JD,Coleman DA,Robinson MH,Rodrigues VC. Interval cancers in a randomized controlled trial of screening for colorectal cancer using a faecal occult blood test. Int J Epidemiol. 1999; 28: 386-390.
  • 6
    Gyrd-Hansen D,Sogaard J,Kronborg O. Analysis of screening data: colorectal cancer. Int J Epidemiol. 1997; 26: 1172-1181.
  • 7
    Church TR,Ederer F,Mandel JS. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test. J Natl Cancer Inst. 1997; 89: 1440-1448.
  • 8
    Neddermeijer HG,Piersma N,Gerrit J,van Oortmarssen GJ,Habbema JDF,Dekker RB. Comparison of response surface methodology and the Nelder and Mead simplex method for optimization in microsimulation models. Rotterdam: Econometric Institute; 1999.
  • 9
    Wright MH. Direct search methods: once scorned, now respectable. In: GriffithsDF, WatsonGA, eds. Numerical analysis 1995 (proceedings of the 1995 Dundee Biennial Conference in Numerical Analysis). United Kingdom: Addison Wesley Longman, Harlow; 1996: 191-208.
  • 10
    Mandel JS,Bond JH,Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993; 328: 1365-1371.
  • 11
    Loeve F,Boer R,van Ballegooijen M,van Oortmarssen G,Habbema JDF. Final report MISCAN-COLON microsimulation model for colorectal cancer. Rotterdam: Department of Public Health, Erasmus University; 1998.
  • 12
    Loeve F,Boer R,van Oortmarssen GJ,van Ballegooijen M,Habbema JDF. The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening. Comput Biomed Res. 1999; 32: 13-33.
  • 13
    Loeve F,Brown ML,Boer R,van Ballegooijen M,van Oortmarssen GJ,Habbema JD. Endoscopic colorectal cancer screening: a cost-saving analysis. J Natl Cancer Inst. 2000; 92: 557-563.
  • 14
    Vogelaar I,van Ballegooijen M,Zauber AG, et al. Model profiler of the MISCAN-Colon microsimulation model for colorectal cancer. Department of Public Health, Erasmus MC, 2004. Available at: Accessed September 9, 2008.
  • 15
    Morson B. The polyp-cancer sequence in the large bowel. Proc R Soc Med. 1974; 67: 451-457.
  • 16
    Muto T,Bussey HJ,Morson BC. The evolution of cancer of the colon and rectum. Cancer. 1975; 36: 2251-2270.
  • 17
    Kyle SM,Isbister WH,Yeong ML. Presentation, duration of symptoms and staging of colorectal carcinoma. Aust N Z J Surg. 1991; 61: 137-140.
  • 18
    Lanier AP,Wychulis AR,Dockerty MB,Elveback LR,Beahrs OH,Kurland LT. Colorectal cancer in Rochester, Minnesota 1940-1969. Cancer. 1973; 31: 606-615.
  • 19
    Majumdar SR,Fletcher RH,Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol. 1999; 94: 3039-3045.
    Direct Link:
  • 20
    Speights VO,Johnson MW,Stoltenberg PH,Rappaport ES,Helbert B,Riggs M. Colorectal cancer: current trends in initial clinical manifestations. South Med J. 1991; 84: 575-578.
  • 21
    Allison JE,Tekawa IS,Ransom LJ,Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996; 334: 155-159.
  • 22
    Collins JF,Lieberman DA,Durbin TE,Weiss DG;Veterans Affairs Cooperative Study #380 Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005; 142: 81-85.
  • 23
    Imperiale TF,Ransohoff DF,Itzkowitz SH,Turnbull BA,Ross ME;Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004; 351: 2704-2714.
  • 24
    Lieberman DA,Weiss DG;Veterans Affairs Cooperative Study Group 380. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001; 345: 555-560.
  • 25
    Petrelli N,Michalek AM,Freedman A,Baroni M,Mink I,Rodriguez-Bigas M. Immunochemical versus guaiac occult blood stool tests: results of a community-based screening program. Surg Oncol. 1994; 3: 27-36.
  • 26
    Robinson MH,Marks CG,Farrands PA,Thomas WM,Hardcastle JD. Population screening for colorectal cancer: comparison between guaiac and immunological faecal occult blood tests. Br J Surg. 1994; 81: 448-451.
  • 27
    Castiglione G,Biagini M,Barchielli A, et al. Effect of rehydration on guaiac-based faecal occult blood testing in colorectal cancer screening. Br J Cancer. 1993; 67: 1142-1144.
  • 28
    Kewenter J,Bjork S,Haglind E,Smith L,Svanvik J,Ahren C. Screening and rescreening for colorectal cancer. A controlled trial of fecal occult blood testing in 27,700 subjects. Cancer. 1988; 62: 645-651.
  • 29
    Levin B,Hess K,Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med. 1997; 157: 970-976.
  • 30
    Macrae FA,St John DJ. Relationship between patterns of bleeding and Hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology. 1982; 82(pt 1): 891-898.
  • 31
    Pignone M,Saha S,Hoerger T,Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137: 96-104.